Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Bloomberg

Pretty Awful Day For Labour: UK Polling Analyst

Polling analyst and Conservative Party peer Robert Hayward says early indications following UK local elections show the results are "as bad as people were predicting for Labour", but London so far appears to be the one exception. Early results suggest a "great night for Reform", according to Hayward. But a full picture of the results might not come into focus until late in the UK day. In an interview on Bloomberg Daybreak Europe, Hayward said it will be a "summer of discontent" for Labour as they argue over whether or not to replace Prime Minister Keir Starmer. He added that he "wouldn't be at all surprised" if this happened over the next few months.

Leia mais: Pretty Awful Day For Labour: UK Polling Analyst
Bloomberg

Why Iran War Risks Hit Indian Stocks Harder

Record foreign outflows and surging energy costs are battering India's economy and the rupee. While geopolitical tensions drive crude prices higher, some sectors show resilience amid the volatility. Lakshmi Iyer of Bajaj Finserv joined Haslinda Amin on Insight to discuss why market corrections offer opportunities and where she sees value in alternatives.

Leia mais: Why Iran War Risks Hit Indian Stocks Harder
Bloomberg

Why China's Rare Earths Grip Is Hard to Break

China's near-total control of the rare earths industry has become one of its most potent geopolitical levers. Chris Kennedy, who leads economic statecraft analysis at Bloomberg Economics, says President Donald Trump is expected to prioritize retaining US access to these industrial inputs, which are vital to the auto, defense and tech sectors.

Leia mais: Why China's Rare Earths Grip Is Hard to Break

Grafa

Artiva Biotherapeutics secures FDA alignment for Phase 3 RA trial after strong Phase 2a results

Artiva Biotherapeutics (NASDAQ:ARTV) has reached a pivotal regulatory milestone, securing FDA alignment for a single Phase 3 registrational trial of its lead candidate, AlloNK, following positive initial data in refractory rheumatoid arthritis (RA).

Leia mais: Artiva Biotherapeutics secures FDA alignment for Phase 3 RA trial after strong Phase 2a results
Grafa

Creative Media & Community Trust reports multifamily growth amid strategic restructuring

Creative Media & Community Trust (NASDAQ:CMCT) reported operating results for the first quarter of 2026, characterized by a dual focus on operational improvement in residential assets and a sweeping overhaul of its capital structure.

Leia mais: Creative Media & Community Trust reports multifamily growth amid strategic restructuring